{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:53:06Z","timestamp":1760953986767},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T00:00:00Z","timestamp":1534377600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"KAKENHI","award":["2450136"],"award-info":[{"award-number":["2450136"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4733-7","type":"journal-article","created":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T12:24:39Z","timestamp":1534422279000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue"],"prefix":"10.1186","volume":"18","author":[{"given":"Tomoya","family":"Yokota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakuni","family":"Serizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumu","family":"Hosokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimihide","family":"Kusafuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Tsubosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,16]]},"reference":[{"key":"4733_CR1","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2188\/jea.JE20120162","volume":"23","author":"Y Lin","year":"2013","unstructured":"Lin Y, Totsuka Y, He Y, et al. Epidemiology of esophageal cancer in Japan and China. J Epidemiol. 2013;23:233\u201342.","journal-title":"J Epidemiol"},{"key":"4733_CR2","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1097\/00000658-199511000-00008","volume":"222","author":"H Fujita","year":"1995","unstructured":"Fujita H, Kakegawa T, Yamana H, et al. Mortality and morbidity rates, postoperative course, quality of life and prognosis after extended radical lymphadenectomy for esophageal cancer. Ann Surg. 1995;222:654\u201362.","journal-title":"Ann Surg"},{"key":"4733_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1245\/s10434-011-2049-9","volume":"19","author":"N Ando","year":"2012","unstructured":"Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68\u201374.","journal-title":"Ann Surg Oncol"},{"key":"4733_CR4","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074\u201384.","journal-title":"N Engl J Med"},{"key":"4733_CR5","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/SLA.0b013e31821111b5","volume":"253","author":"R Gertler","year":"2011","unstructured":"Gertler R, Stein HJ, Langer R, et al. Long-term outcome of 2920 patients with cancers of the esophagus and esophagogastric junction: evaluation of the new union Internationale Contre le Cancer\/American joint Cancer committee staging system. Ann Surg. 2011;253:689\u201398.","journal-title":"Ann Surg"},{"key":"4733_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.cancergen.2015.05.001","volume":"208","author":"M Serizawa","year":"2015","unstructured":"Serizawa M, Yokota T, Hosokawa A, et al. The efficacy of uracil DNA glycosylase pretreatment in amplicon-based massively parallel sequencing with DNA extracted from archived formalin-fixed paraffin-embedded esophageal cancer tissues. Cancer Genet. 2015;208:415\u201327.","journal-title":"Cancer Genet"},{"key":"4733_CR7","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1373\/clinchem.2012.202390","volume":"59","author":"H Do","year":"2013","unstructured":"Do H, Wong SQ, Li J, Dobrovic A. Reducing sequence artifacts in amplicon-based massively parallel sequencing of formalin-fixed paraffin-embedded DNA by enzymatic depletion of uracil-containing templates. Clin Chem. 2013;59:1376\u201383.","journal-title":"Clin Chem"},{"key":"4733_CR8","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/nm791","volume":"8","author":"RL Camp","year":"2002","unstructured":"Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002;8:1323\u20137.","journal-title":"Nat Med"},{"key":"4733_CR9","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1200\/JCO.2015.64.2322","volume":"34","author":"T Kawaguchi","year":"2016","unstructured":"Kawaguchi T, Koh Y, Ando M, et al. Prospective analysis of oncogenic driver mutations and environmental factors: Japan molecular epidemiology for lung cancer study. J Clin Oncol. 2016;34:2247\u201357.","journal-title":"J Clin Oncol"},{"key":"4733_CR10","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/ng.3076","volume":"46","author":"YB Gao","year":"2014","unstructured":"Gao YB, Chen ZL, Li JG, et al. Genetic landscape of esophageal squamous cell carcinoma. Nat Genet. 2014;46:1097\u2013102.","journal-title":"Nat Genet"},{"key":"4733_CR11","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/nrg1879","volume":"7","author":"JA Engelman","year":"2006","unstructured":"Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7:606\u201319.","journal-title":"Nat Rev Genet"},{"key":"4733_CR12","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","volume":"129","author":"BD Manning","year":"2007","unstructured":"Manning BD, Cantley LC. AKT\/PKB signaling: navigating downstream. Cell. 2007;129:1261\u201374.","journal-title":"Cell"},{"key":"4733_CR13","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","volume":"296","author":"LC Cantley","year":"2002","unstructured":"Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296:1655\u20137.","journal-title":"Science"},{"key":"4733_CR14","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1053\/j.gastro.2016.01.035","volume":"150","author":"G Sawada","year":"2016","unstructured":"Sawada G, Niida A, Uchi R, et al. Genomic landscape of esophageal squamous cell carcinoma in a Japanese population. Gastroenterology. 2016;150:1171\u201382.","journal-title":"Gastroenterology"},{"key":"4733_CR15","first-page":"231","volume":"13","author":"H Zheng","year":"2016","unstructured":"Zheng H, Wang Y, Tang C, et al. TP53, PIK3CA, FBXW7 and KRAS mutations in esophageal Cancer identified by targeted sequencing. Cancer Genomics Proteomics. 2016;13:231\u20138.","journal-title":"Cancer Genomics Proteomics"},{"key":"4733_CR16","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.humpath.2013.09.011","volume":"45","author":"J Hou","year":"2014","unstructured":"Hou J, Jiang D, Zhang J, et al. Frequency, characterization, and prognostic analysis of PIK3CA gene mutations in Chinese esophageal squamous cell carcinoma. Hum Pathol. 2014;45:352\u20138.","journal-title":"Hum Pathol"},{"key":"4733_CR17","doi-asserted-by":"publisher","unstructured":"Maeng CH, Lee J, van Hummelen P, et al.. High-throughput genotyping in metastatic esophageal squamous cell carcinoma identifies phosphoinositide-3-kinase and BRAF mutations. PLoS One. 2012: 7. doi: https:\/\/doi.org\/10.1371\/journal.pone.0041655 .","DOI":"10.1371\/journal.pone.0041655"},{"key":"4733_CR18","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jss.2007.03.044","volume":"145","author":"R Mori","year":"2008","unstructured":"Mori R, Ishiguro H, Kimura M, et al. PIK3CA mutation status in Japanese esophageal squamous cell carcinoma. J Surg Res. 2008;145:320\u20136.","journal-title":"J Surg Res"},{"key":"4733_CR19","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1158\/1078-0432.CCR-12-3559","volume":"19","author":"H Shigaki","year":"2013","unstructured":"Shigaki H, Baba Y, Watanabe M, et al. PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma. Clin Cancer Res. 2013;19:2451\u20139.","journal-title":"Clin Cancer Res"},{"key":"4733_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature13176","volume":"509","author":"Y Song","year":"2014","unstructured":"Song Y, Li L, Ou Y, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;509:91\u20135.","journal-title":"Nature"},{"key":"4733_CR21","doi-asserted-by":"publisher","unstructured":"Wang L, Shan L, Zhang S, et al. PIK3CA gene mutations and overexpression: implications for prognostic biomarker and therapeutic target in Chinese esophageal squamous cell carcinoma. PLoS One. 2014. 9 doi: https:\/\/doi.org\/10.1371\/journal.pone.0103021 .","DOI":"10.1371\/journal.pone.0103021"},{"key":"4733_CR22","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.3748\/wjg.v23.i14.2585","volume":"23","author":"SY Liu","year":"2017","unstructured":"Liu SY, Chen W, Chughtai EA, et al. PIK3CA gene mutations in Northwest Chinese esophageal squamous cell carcinoma. World J Gastroenterol. 2017;23:2585\u201391.","journal-title":"World J Gastroenterol"},{"key":"4733_CR23","doi-asserted-by":"crossref","first-page":"30691","DOI":"10.18632\/oncotarget.8749","volume":"7","author":"HS Kim","year":"2016","unstructured":"Kim HS, Lee SE, Bae YS, et al. PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma. Oncotarget. 2016;7:30691\u2013701.","journal-title":"Oncotarget"},{"key":"4733_CR24","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1002\/ijc.21706","volume":"118","author":"WA Phillips","year":"2006","unstructured":"Phillips WA, Russell SE, Ciavarella ML, et al. Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett\u2019s esophagus. Int J Cancer. 2006;118:2644\u20136.","journal-title":"Int J Cancer"},{"key":"4733_CR25","doi-asserted-by":"publisher","first-page":"5486","DOI":"10.1038\/onc.2008.244","volume":"27","author":"L Zhao","year":"2008","unstructured":"Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene. 2008;27:5486\u201396.","journal-title":"Oncogene"},{"key":"4733_CR26","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1038\/aps.2013.163","volume":"34","author":"WF Wang","year":"2013","unstructured":"Wang WF, Xie Y, Zhou ZH, Qin ZH, Wu JC, He JK. PIK3CA hypomethylation plays a key role in activation of the PI3K\/AKT pathway in esophageal cancer in Chinese patients. Acta Pharmacol Sin. 2013;34:1560\u20137.","journal-title":"Acta Pharmacol Sin"},{"key":"4733_CR27","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1158\/1078-0432.CCR-11-2410","volume":"18","author":"X Liao","year":"2012","unstructured":"Liao X, Morikawa T, Lochhead P, et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res. 2012;18:2257\u201368.","journal-title":"Clin Cancer Res"},{"key":"4733_CR28","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","volume":"11","author":"W De Roock","year":"2010","unstructured":"De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11:753\u201362.","journal-title":"Lancet Oncol"},{"key":"4733_CR29","doi-asserted-by":"publisher","first-page":"6956","DOI":"10.1158\/1078-0432.CCR-09-1165","volume":"15","author":"Y He","year":"2009","unstructured":"He Y, Veer LJVT, Mikolajewska-Hanclich I, et al. PIK3CA mutations predict local recurrences in rectal cancer patients. Clin Cancer Res. 2009;15:6956\u201362.","journal-title":"Clin Cancer Res"},{"key":"4733_CR30","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1200\/JCO.2008.18.6544","volume":"27","author":"S Ogino","year":"2009","unstructured":"Ogino S, Nosho K, Kirkner GJ, et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol. 2009;27:1477\u201384.","journal-title":"J Clin Oncol"},{"key":"4733_CR31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.lungcan.2006.07.006","volume":"54","author":"O Kawano","year":"2006","unstructured":"Kawano O, Sasaki H, Endo K, et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer. 2006;54:209\u201315.","journal-title":"Lung Cancer"},{"key":"4733_CR32","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.1158\/1078-0432.CCR-09-0632","volume":"15","author":"K Kalinsky","year":"2009","unstructured":"Kalinsky K, Jacks LM, Heguy A, et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res. 2009;15:5049\u201359.","journal-title":"Clin Cancer Res"},{"key":"4733_CR33","doi-asserted-by":"publisher","first-page":"6064","DOI":"10.1158\/1078-0432.CCR-07-0266","volume":"13","author":"M Barbareschi","year":"2007","unstructured":"Barbareschi M, Buttitta F, Felicioni L, et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res. 2007;13:6064\u20139.","journal-title":"Clin Cancer Res"},{"key":"4733_CR34","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/j.humpath.2012.03.011","volume":"43","author":"M Rahman","year":"2012","unstructured":"Rahman M, Nakayama K, Rahman MT, et al. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. Hum Pathol. 2012;43:2197\u2013206.","journal-title":"Hum Pathol"},{"key":"4733_CR35","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jmoldx.2013.05.003","volume":"15","author":"RR Singh","year":"2013","unstructured":"Singh RR, Patel KP, Routbort MJ, et al. Clinical validation of a next generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn. 2013;15:607\u201322.","journal-title":"J Mol Diagn"},{"key":"4733_CR36","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/nbt.2198","volume":"30","author":"NJ Loman","year":"2012","unstructured":"Loman NJ, Misra RV, Dallman TJ, et al. Performance comparison of benchtop high-throughput sequencing platforms. Nat Biotechnol. 2012;30:434\u20139.","journal-title":"Nat Biotechnol"},{"key":"4733_CR37","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S1525-1578(10)60571-5","volume":"7","author":"S Ogino","year":"2005","unstructured":"Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn. 2005;7:413\u201321.","journal-title":"J Mol Diagn"},{"key":"4733_CR38","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.trsl.2010.05.007","volume":"156","author":"T Yokota","year":"2010","unstructured":"Yokota T, Shibata N, Ura T, et al. Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)\/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer. Transl Res. 2010;156:98\u2013105.","journal-title":"Transl Res"},{"key":"4733_CR39","first-page":"3165","volume":"55","author":"M Toyooka","year":"1995","unstructured":"Toyooka M, Konishi M, Kikuchi-Yanoshita R, Iwama T, Miyaki M. Somatic mutations of the adenomatous polyposis coli gene in gastroduodenal tumors from patients with familial adenomatous polyposis. Cancer Res. 1995;55:3165\u201370.","journal-title":"Cancer Res"},{"key":"4733_CR40","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1042\/BJ20131412","volume":"458","author":"LM Hare","year":"2014","unstructured":"Hare LM, Phesse TJ, Waring PM, et al. Physiological expression of the PI3K-activating mutation Pik3ca(H1047R) combines with Apc loss to promote development of invasive intestinal adenocarcinomas in mice. Biochem J. 2014;458:251\u20138.","journal-title":"Biochem J"},{"key":"4733_CR41","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1038\/onc.2013.167","volume":"33","author":"DA Deming","year":"2014","unstructured":"Deming DA, Leystra AA, Nettekoven L, et al. PIK3CA and APC mutations are synergistic in the development of intestinal cancers. Oncogene. 2014;33:2245\u201354.","journal-title":"Oncogene"},{"key":"4733_CR42","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/labinvest.2014.77","volume":"94","author":"J Zhang","year":"2014","unstructured":"Zhang J, Jiang D, Li X, et al. Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery. Lab Investig. 2014;94:917\u201326.","journal-title":"Lab Investig"},{"issue":"2","key":"4733_CR43","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.athoracsur.2014.03.015","volume":"98","author":"W Zhang","year":"2014","unstructured":"Zhang W, Zhu H, Liu X, et al. Epidermal growth factor receptor is a prognosis predictor in patients with esophageal squamous cell carcinoma. Ann Thorac Surg. 2014;98(2):513\u20139.","journal-title":"Ann Thorac Surg"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4733-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4733-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4733-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T21:29:54Z","timestamp":1604784594000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4733-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,16]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4733"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4733-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,16]]},"assertion":[{"value":"19 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by institutional review boards in Shizuoka Cancer Center and Toyama University (approval number: Shizuoka Cancer Center, T23\u20133; Toyama University, 22\u201396). Written informed consent to participate in the study was obtained from each study participant in Toyama University. However, the need for individual informed consent to participate in the study has been waived by institutional review boards in Shizuoka Cancer Center (approval number: Shizuoka Cancer Center, T23\u20133), as this study was retrospective exploratory research.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"826"}}